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Abstract
Background: Stroke caused by brain ischemia is the third leading cause of adult disability. Active prevention and
early treatment of stroke targeting the causes and risk factors may decrease its incidence, mortality and
subsequent disability. Pien Tze Huang (PZH), a Chinese medicine formula, was found to have anti-edema, anti-
inflammatory and anti-thrombotic effects that can prevent brain damage. This study aims to investigate the
potential mechanisms of the preventive effects of Pien Tze Huang on brain damage caused by chronic ischemia
and hypertensive stroke in rats.
Methods: The effects of Pien Tze Huang on brain protein expression in spontaneously hypertensive rat (SHR) and
stroke prone SHR (SHRsp) were studied with 2-D gel electrophoresis and mass spectrometric analysis with a matrix-
assisted laser desorption/ionization time-of-flight (MALDI-TOF)/TOF tandem mass spectrometer and on brain cell
death with enzyme link immunosorbent assay (ELISA) and immunostaining.
Results: Pien Tze Huang decreased cell death in hippocampus and cerebellum caused by chronic ischemia and
hypertensive stroke. Immunostaining of caspase-3 results indicated that Pien Tze Huang prevents brain cells from
apoptosis caused by ischemia. Brain protein expression results suggested that Pien Tze Huang downregulated
QCR2 in the electron transfer chain of mitochondria preventing reactive oxygen species (ROS) damage and possibly
subsequent cell death (caspase 3 assay) as caused by chronic ischemia or hypertensive stroke to hippocampus and
cerebellum.
Conclusion: Pien Tze Huang showed preventive effects on limiting the damage or injury caused by chronic
ischemia and hypertensive stroke in rats. The effect of Pien Tze Huang was possibly related to prevention of cell
death from apoptosis or ROS/oxidative damage in mitochondria.
Background
Cerebral ischemia and stroke are the major causes of
mortality and morbidity worldwide [1-4]. In the West,
no effective treatment is available for ischemic stroke,
apart from the use of aspirin and thrombolytic treat-
ment such as tissue plasminogen activator [5]. In China,
Chinese medicinal herbs have been used to treat cere-
bral stroke [6]. A meta-analysis of 191 trials of 22 herbal
drugs found significant positive effects; however, the
overall methodological quality of these trials was ques-
tionable [7,8]. The mechanisms of most herbal treat-
ments have not been fully established [9,10].
Hypertension is the most important risk factor for
ischemic stroke [1,2,11] which is often studied with ani-
mal models [12-14]. For example, the spontaneously
hypertensive rat (SHR) bred from the progenitor Wistar
Kyoto (WKY) rat develops hypertension spontaneously
[15,16]. Stroke prone SHR (SHRsp), which has dimin-
ished cerebral arteries and thickened vessels, is charac-
terized by 100% spontaneous hypertension and 80%
cerebral stroke [17,18]. SHR and SHRsp can be used to * Correspondence: david-yew@cuhk.edu.hk
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ischemia and hypertensive stroke respectively [17-19].
Pien Tze Huang (PZH), a herbal formula documented
during the Ming Dynasty (circa 1555 AD) in China,
contains musk, Calculus Bovis (Niuhuang,o x ’s gall-
stone), Shedan (snake’s gall) and Panax notoginseng
(Tianqi or Sanqi) and is used to treat liver diseases, can-
cer and inflammation [20]. Our previous studies found
that PZH protected the liver from carbon tetrachloride
damage [20] and that PZH showed anti-cancer activities
[21]. Our studies on Gingko suggested the possible gen-
eral molecular mechanisms of neuroprotective effects
[6,22,23], including apoptosis, oxidative stress, free radi-
cal in the brain cells. The components of PZH possess
anti-edema, anti-inflammatory and anti-thrombotic
effects [9,24,25].
T h ep r e s e n ts t u d ya i m st oi n v e s t i g a t et h ep o t e n t i a l
mechanisms for PZH’s neuroprotective effects in treat-
ing cerebral ischemia and hypertensive stroke in the
SHR and SHRsp models.
Methods
Reagents and chemicals
All chemicals and reagents used in this study were pur-
chased from Sigma-Aldrich (USA) or MERCK (USA)
unless otherwise specified.
Grouping and treatment of animals
M a l eS H Ra g e d3m o n t h sa n da g e -a n ds e x - m a t c h e d
control WKY rats were obtained from the Laboratory
Animal Services Centre (Chinese University of Hong
Kong, Hong Kong, China). Six-week old male SHRsp
were obtained from the Institute of Laboratory Animal
Science (Chinese Academy of Medical Sciences, Beijing,
China). Housed in a room with 12 hour light-dark cycle
(temperature 22-23°C and humidity 45-55%), the rats
were given ad libitum access to standard laboratory
rodent chow and water. The experiments were approved
by the Animal Experimentation Ethics Committee of
The Chinese University of Hong Kong.
Five groups of SHR and WKY were set up for immu-
nostaining, proteomic analysis and cell death assay
(Table 1). Briefly, Group 1: SHR for the preventive
effects of PZH on ischemia (immunostaining and pro-
teomics); Group 2: control for Group 1; Groups 3 and
4: SHR and WKY respectively for the preventive effects
of PZH on ischemia (cell death assay); Group 5: SHRsp
for the preventive effects of PZH on stroke.
Rats in Groups 1 (n = 30) and 2 (n = 20) were ran-
domly divided into ischemia with two PZH treatments
(n = 15) and two ischemia control (n =1 0 )g r o u p s
respectively. Rats were given daily intra-gastric adminis-
tration of 18 mg/kg PZH in normal saline suspension
for three months before common carotid artery (CCA)
ligation. Normal saline was given to rats with no PZH
feeding daily.
For cell death assay, 18 SHR (Group 3) and 18 WKY
(Group 4) were randomly divided into three groups (6
rats per group): (1) ischemia with PZH treatment, (2)
ischemia control and (3) sham operation control. In the
ischemia with PZH treatment group, before CCA liga-
tion, rats were given daily intra-gastric administration of
PZH at a dosage of 18 mg/kg for three months. The
rats in ischemia control group also had intra-gastric
Table 1 Summary of rat groups for experiments
Group Animal Age Sub-group No. PZH* Ligation Assay Remark
1 SHR 3 m 1A 15 Yes Yes I The ischemia with PZH treatment group
1B 15 Yes Yes P The ischemia with PZH treatment group
2 SHR 3 m 2A 10 No Yes I The ischemia group, control for 1A
2B 10 No Yes P The ischemia group, control for 1B
3 SHR 3 m 3A 6 Yes Yes C The ischemia with PZH treatment group
3B 6 No Yes C The ischemia group, control for 3A
3C 6 No Sham C The sham operation group, control for 3B
4 WKY 3 m 4A 6 Yes Yes C The ischemia with PZH treatment group
4B 6 No Yes C The ischemia group, control for 4A
4C 6 No Sham C The sham operation group, control for 4B
5 SHRsp 7 w 5A 17 Yes
# NA C Preventive effects of PZH in stroke





C: Cell death detected by ELISA.
* PZH was given for 3 months before the time of ligation, except for Group 5..
# For Group 5A, PZH was given until the brain stroke occurred.
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operation. The rats in the sham operation control group
were not ligated.
The 34 six-week old SHRsp rats (Group 5) were given
one week to adapt to the new environment. Then the
rats were randomly divided into two groups: (1) 17
SHRsp rats were given 18 mg/kg PZH daily until stroke
occurred and thereafter normal saline were given, (2)
the rest 17 SHRsp rats were given normal saline. The
rats were monitored closely everyday until signs of
stroke were noted. The SHRsp rats would develop
stroke spontaneously around 12-14 weeks [15,16]. Neu-
rological status of each SHRsp was evaluated carefully
by one observer who had no knowledge of the grouping.
A grading scale of 0 to 4 was used to assess the extent
of stroke (Table 2); scores 1 and 2 are regarded as hav-
i n gm i l ds t r o k ea n d3a n d4a ss e v e r es t r o k e[ 2 6 ] .I fa
rat exhibited the appropriate behavior at one step but
not at the subsequent step, it was graded as the former.
Neurological examinations were performed at 9:00 and
15:00 daily. Score was recorded when stroke was first
noted. Once the stroke was confirmed, the feeding of
PZH or saline solution would be terminated. Dates of
the onset of stroke and the subsequent death were
recorded.
Ligation of common carotid arteries
Permanent occlusion of bilateral common carotid
arteries (CCA) was modified from previously published
methods [27,28] as follows. Bilateral CCA were ligated
and excised to avoid incomplete occlusion and possible
re-supply of blood flow. All equipments and tools (for-
ceps, scissors, clamps, needles, knives, cotton, gauze and
threads) were sterilized. Rats were anaesthetized by
intra-peritoneal injection with 10% chloral hydrate (3
mg/kg) and placed in supine position. Hair was trimmed
off the fore-neck area and skin was disinfected with 70%
ethanol. A cut was made along the middle line for 1.5-2
cm and subcutaneous tissue was separated to expose the
CCA located beside the thyroid gland. Distal and proxi-
mal ends of CCA were bound with 5.0 threads leaving a
gap of about 0.5 cm between the two ends and the CCA
was excised between the two ends. After suturing, peni-
cillin and Temgesic (Buprenorphine) were given. Rats
were returned to the cage when they could move and
showed no abnormal behavior.
Brain tissue sampling
Animal model of CCA ligation is used to study chronic
ischemia effects [27,28]. Rats in Groups 1 to 4 were
sacrificed two weeks following the operation, while rats
in Group 5 died from stroke. For caspase-3 immunos-
taining, the rats of Groups 1A and 2A were anaesthe-
tized with intra-peritoneal injection of 10% chloral
hydrate (1 mg/kg). The heart was exposed after the
thorax cavity was opened up. The perfusion was per-
formed by pumping phosphate buffered saline (PBS)
from the left ventricle and drained out from an opening
in the right atrium. When the color of the liver turned
from red to white, the perfusion continued with 300 ml
of 4% paraformaldehyde (PFA) in PBS. The brain was
then removed and further fixed overnight in 4% PFA.
For immunostaining, different brain regions were dis-
sected out into 5 mm long blocks which were dehy-
drated through a series of ethanol then cleared in
xylene. The blocks were embedded and sectioned into 5
μm in coronal position for caspase-3 immunostaining.
For cell death assay and proteomic analysis, the rats of
Groups 1 to 4 were decapitated and the brains were
removed immediately. Tissues from hippocampus and
cerebellum were sampled and after snap frozen in liquid
nitrogen stored at -80°C until analysis. Upon the death
o ft h er a t so fG r o u p5 ,t h eb r a i n sw e r es i m i l a r l y
removed and hippocampus and cerebellum were dis-
sected out and stored at -80°C until analyses for cell
death index with enzyme link immunosorbent assay
(ELISA) kits (Roche Diagnostics, Germany). The hippo-
c a m p u sw a sc h o s e na st h i si st h ea r e ao ft h em i d - b r a i n
area most susceptible to ischemia induced by the CCA
ligation, while the blood supply to the posterior part of
the brain such as cerebellum would be less affected
because the vertebral arteries were intact [29].
Immunostaining for cleaved caspase-3
Immunostaining was performed according to our pre-
viously published method [30] with primary antibody
for caspase-3. All solutions for the immunostaining were
diluted with 1× PBS unless otherwise stated. The tissue
sections were first immersed in 0.1% Triton X-100 for
10 minutes, rinsed with PBS, incubated with 3% hydro-
gen peroxide (H2O2) in absolute methanol for 30 min-
utes and then rinsed again. Bovine serum albumin of
0.1% was used as non-specific antigen blocking solution
for one hour, the sections were incubated with diluted
H Capase-3 (1:500) (9662, Cell Signaling Technology,
Table 2 Stroke scoring
Grade Score Criteria
Normal 0 No observable deficit.
Mild 1 Slight reduction of activities or mild excitation.
2 Significant reduction of activities or hyperirritability.
Severe 3 Unable to walk, decreased responsiveness.
4 Unable to stand, limb paralysis, or paralysis of one side
of the body.
The severity of stroke in stroke prone spontaneously hypertensive rats (SHRsp)
was assessed with the neurologic examination grading system of stroke as
previously reported [26]. When the score was 1 or 2, the severity of stroke
was mild, and when the score was 3 or 4, the severity was severe.
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were rinsed with PBS and incubated in diluted anti-rab-
bit secondary antibody (1:1,000) for two hours. The sec-
tions were then rinsed and incubated in diluted
streptavidin horseradish peroxidase conjugated solution
(1:200; Zymed® Laboratories, USA) for two hours. Tissue
sections for negative control were processed similarly
b u tw i t h o u tp r i m a r ya n t i b o d ya d d e d .A f t e rt h ep r i m a r y
and secondary antibody reactions, the sections were sub-
sequently reacted with Vectastain ABC-Peroxidase kit
(Vector Laboratories, USA) for visualization of the posi-
tive cells according to our previously reported method
[30]. Briefly, three consecutive slides were used for
counting with a grid of 100 small squares in a 1.0 × 9 ×
1.0 mm
2 was put into the eyepiece. Four areas measur-
ing each 0.4 × 0.4 mm
2 were counted in each slide.
Selection of the grid area was automatic and random by
the Neurolucida 2000 software version 4.10d (MBF
Bioscience, USA).
Cell death by ELISA
Cell death detection ELISA (Roche Diagnostics, Ger-
many) assays were carried out according to the manu-
facturer’s procedures for detecting histone-associated
DNA fragments or nucleosomes that were released from
DNA degradation during apoptosis. The kit can be used
for cell culture as well as different tissue homogenate
samples including frozen brain tissue [31-34]. The cyto-
solic fraction was prepared from brain tissue sample
homogenized in 0.5 ml of lysis buffer, i.e. 50 mM Tris-
HCl (pH7.4) containing 150 mM NaCl, 5 mM EDTA,
0.1% sodium dodecyl sulphate (SDS), 1% Triton X-100,
0.1 mg/ml PMSF, 1 mg/ml leupeptin, 1 mg/ml pepstatin
Aa n d5μg/ml aprotinin. The homogenate was centri-
fuged at 14,000 rpm (Eppendorf, Germany) for 30 min-
utes at 4°C and the supernatant obtained was either
i m m e d i a t e l yu s e do rs t o r e da t- 8 0 ° Cu n t i la n a l y s i s .T h e
protein concentration of the extract was determined
with the protein assay (BioRad Laboratories, USA). For
the ELISA, 100 μl of anti-histone antibody solution was
added into each well of the microplate, then covered
with the adhesive cover foil and incubated for one hour
at ambient temperature (15-25°C). After incubation, the
antibody solution was replaced by 200 μlo fi n c u b a t i o n
buffer for a further incubation of 30 minutes. The wells
were then washed three times with 250 μlo fw a s h i n g
solution. Samples (100 μl) were added into the wells for
incubation of 90 minutes. For the blank readings, incu-
bation buffer was added instead of the samples. After
incubation, wells were washed three times with 250 μl
of washing solution followed by 100 μl of conjugate
solution containing anti-DNA-peroxidase into each well
except the blanks. After another incubation of 90 min-
utes, the wells were washed three times with 250 μlo f
washing solution followed by 100 μl of substrate solu-
tion. The plate was read at 405 nm against the blanks.
Results were expressed as absorbance at 405 nm per mg
of protein.
Proteomic analysis
Comparative proteomic techniques were used to deter-
mine the preventive effect of PZH on the brain [35-37].
Hippocampus and cerebellum samples (stored at -80°C)
from the ischemia with PZH treatment (Group 1B) and
ischemia control (Group 2B) groups were prepared in
lysis buffer (7 M urea, 2 M thiourea, 0.01% TBP, 4%
CHAP and 0.01% NP 40) with protease inhibitors (GE
Healthcare Life Sciences, Sweden). After total protein
concentration determined with PlusOne™ 2D Quant kit
(GE Healthcare Life Sciences, Sweden), equal amounts
of samples of the same group were pooled into one sin-
gle sample. Therefore there were four samples from two
brain regions of each group. The four samples were run
in triplicates (total 12 gels) and proteins were resolved
with two-dimensional (2D) gel electrophoresis and silver
staining. Differentially expressed spots were selected for
mass spectrometry (MS) identification with a matrix-
assisted laser desorption/ionization time-of-flight
(MALDI-TOF)/TOF tandem MS as described in our
previous publications [9,38].
Two-dimensional gel electrophoresis
All experiments of 2D gel electrophoresis were per-
formed following the modified protocol of GE Health-
care Life Sciences (Sweden). Briefly, samples (150 μg)
were loaded onto immobilized pH strips. Isoelectric
focusing was performed on Ettan™ IPGphor™ Isoelectric
Focusing System (GE Healthcare Life Sciences, Sweden)
with a total voltage-hour (Vh) of 57730 progressively
increased from low to high voltage (30 V, 150 V, 500 V,
1000 V to 3500 V). After equilibration in buffer (50 mM
Tris-HCl, 6 M urea, 30% v/v glycerol, 2% w/v SDS,
0.002% w/v bromophenol blue) with 100 mg/10 ml
DTT for 15 minutes, and then with 250 mg/10 ml
iodoacetamide in the same buffer for another 15 min-
utes, the second dimension was separated by 11% SDS-
PAGE gel at 75 V for 16 hours. After silver staining
(PlusOne™ Silver Staining kit, GE Healthcare Life
Sciences, Sweden), gels were scanned with an Image
Scanner (GE Healthcare Life Sciences, Sweden). Image
analysis was performed with ImageMaster™ 2D Platinum
V.5.0 software (GE Healthcare Life Sciences, Sweden).
The spots of differentially expressed proteins (fold dif-
ference ≥2) were excised from the gels and the ischemia
with PZH treatment (1B) and ischemia control (2B)
groups were compared [39]. The excised gel pieces were
destained and digested with 8-10 μl modified sequencing
grade trypsin (20 ng/μl) (Promega, USA) at 30°C for 14-
16 hours. Tryptic peptides were extracted with
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in 50% acetonitrile for 10 minutes.
Protein identification with mass spectrometry
Proteins were identified with a MALDI-TOF/TOF tan-
dem mass spectrometer ABI 4700 proteomics analyzer
(Applied Biosystems, USA). For acquisition of mass
spectra, 0.5 μl samples were spotted onto a MALDI
plate, followed by 0.5 μlm a t r i xs o l u t i o n( 4m g / m la-
cyano-4-hydroxycinnamic acid in 35% acetonitrile and
1% trifluoroacetic acid). Mass data acquisitions were
piloted by 4000 Series Explorer™ Software (version 3.0,
Applied Biosystems, CA, USA) with batched-processing
and automatic switching between MS and MS/MS
modes. All MS survey scans were acquired over the
mass range 700-3500 m/z in the reflectron positive-ion
mode. The MS spectra were internally calibrated with
porcine trypsin autolytic products (m/z 842.509, m/z
1045.564, m/z 1940.935 and m/z 2211.104). The MS
peaks (MH+) were detected on minimum S/N ratio≥20
and cluster area S/N threshold≥25 without smoothing
and raw spectrum filtering. The filtered precursor ions
with a user-defined threshold (S/N ratio≥50) were
selected for the MS/MS scan. Fragmentation of precur-
sor ions was performed with MS-MS 1 kV positive
mode with collision-induced dissociation on and argon
as the collision gas. MS/MS spectra were accumulated
from 3000 laser shots with default calibration with Glu-
Fibrinopeptide B from 4700 Calibration Mixture
(Applied Biosystems, USA). The MS/MS peaks were
detected on minimum S/N ratio≥3 and cluster area S/N
threshold≥15 with smoothing.
T h eM Sa n dM S / M Sd a t aw e r el o a d e di n t ot h eG P S
Explorer™ software (version 3.5, Applied Biosystems,
USA) and searched against NCBInr protein database by
Mascot search engine (version 1.9.05, Matrix science,
UK) with combined MS (peptide-mass-fingerprint
approach) with MS/MS (DeNovo sequencing approach)
analysis for protein identification. Search parameters
were as follows: monoisotopic peptide mass (MH+);
700-3500 Da; one missed cleavage per peptide; enzyme,
trypsin; taxonomy, Mus; pI, 0-14; precursor-ion mass
tolerance, 50 ppm; MS/MS fragment-ion mass tolerance,
0.1 Da; variable modifications, oxidation for methionine.
Top ten hits for each protein search were reported. Pro-
teins with MOWSE score greater than 70 and at least
four matched peptides were accepted as identified.
Functional annotation
Functional annotation and clustering were performed
for the differentially expressed proteins as identified by
MS with software available from two web sites, namely
Database for Annotation, Visualization and Integrated
Discovery (DAVID) [40,41], and Gene Ontology Tree
Machine (GOTM) [42]. DAVID and GOTM are tools
for data analysis and visualization for sets of genes or
their products, i.e. proteins, using the Gene Ontology
(GO) and the Gene Ontology Consortium 2000 which is
a structured and precisely defined vocabulary for
describing the roles of genes and their products with
respect to biological process, molecular function and
cellular component of the genes’ products. In the analy-
sis, the background list for rat (Rattus norvegicus)w a s
selected. Subsets of proteins were clustered according to
the functional annotations of the differentially expressed
protein lists. When the enrichment score was greater
than 1.0 and P value was less than 0.05 for a cluster, the
clustering of these proteins was regarded as significant.
Individual protein in the significant clusters with P value
(with multiple testing corrections) of less than 0.05 was
regarded as the protein functionally significant for the
term of the cluster and the protein.
Statistical Analysis
All data were randomized during recording and were
later presented as mean ± standard deviation (SD) after
grouping. Student’s t-test was performed to evaluate the
differences between groups for cell death assay and
cleaved caspase-3 immunostaining results between the
two SHRsp groups. For the cell death assay results of
the three SHR and WKY groups, analysis of variance
(ANOVA) was used to test the statistical significance of
the differences among groups and post hoc test (with
Bonferroni correction for multiple comparisons) was
used to compare individual pairs of groups. The stroke
scores of the SHRsp groups were analyzed with Chi-
square test and the means of the time of survival after
stroke of the SHRsp groups were analyzed with Stu-
dent’s t-test. A difference was considered statistically
significant when P value was less than 0.05.
Results
Cell death assay
We evaluated the cell deaths in hippocampus in the
SHR (i.e. Groups 3A, 3B and 3C), WKY (i.e. Groups 4A,
4B and 4C) and SHRsp (i.e. Groups 5A and 5B) rats
after ligation (with and without PZH treatment) or
sham operation. The WKY (F = 7.55, P = 0.005) and
SHR (F = 32.22, P < 0.001) groups showed significant
differences in hippocampus and the post hoc tests
showed that the ischemia WKY and SHR groups had
significantly higher cell deaths (0.508 ± 0.148 and 0.814
± 0.162 respectively) than the WKY and SHR sham
operation groups (0.336 ± 0.085 and 0.405 ± 0.099
respectively) (WKY: P = 0.017; SHR: P < 0.001) (Figure
1A). Importantly, cell deaths in the ischemia with PZH
treatment WKY and SHR groups (0.265 ± 0.085 and
0.305 ± 0.066) showed no significant difference as com-
pared to their respective sham operation groups (Figure
1A), suggesting that PZH significantly decreased the cell
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in both hypertensive and normotensive rats, SHR and
WKY respectively. In cerebellum there was no signifi-
cant difference between the sham operation control,
ischemia control and PZH treatment groups (Figure 1B).
The hippocampus and cerebellum samples obtained
from the SHRsp showed that there were significantly
less cell deaths in the PZH treated group (Group 5A)
when compared to the control (Group 5B) in the hippo-
campus (Group 5A: 1.17 ± 0.44; Group 5B: 2.16 ± 0.54;
Figure 1 Cell death assay results in SHR and WKY. Cell death assay results in (1A) hippocampus and (1B) cerebellum samples from sham
operation, ischemia and ischemia with PZH treatment groups of WKY and SHR two weeks after the ligation operation. For hippocampus (1A), in
both WKY and SHR, ischemia significantly increased the cell death as compared to the sham operation groups (*P < 0.05). PZH protected
hippocampus from the damage induced by ischemia and showed significant decreases (**P < 0.05) as compared to the ischemia groups. For
cerebeullum (1B) there was no significant difference between the cell death result of the WKY and SHR groups.
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0.018) (Figure 2), suggesting that PZH preventive treat-
ment played a significant protective role against cell
deaths caused by stroke in the hippocampus and
cerebellum.
SHRsp stroke and scores
Initially, there were 17 SHRsp rats each in Groups 5A and
5B, but three rats died in Group 5A shortly after the
experiment started. Using the scores from the grading sys-
tem of stroke, we compared the severity of stroke between
Group 5A, rats with PZH treatment before stroke and
Group 5B, controls with no PZH treatment. When SHRsp
were categorized by initial stroke scores, 8 out of 14 (57%)
of PZH treatment rats had mild scores of 1 or 2 compared
to 11 out of 17 (65%) of the control SHRsp that had severe
scores of 3 or 4, although this trend was not statistically
significant (Table 3). Furthermore, group PZH treated
SHRsp did not show significant differences in the means
of scores, time of onset of stroke and time of death com-
pared with the control rats (Table 4). Nevertheless, one
significant difference noted was the time interval between
the onset of stroke and death. PZH showed significant
delay (P < 0.001) of death of PZH treated rats after stroke
had occurred when compared to the control rats by 2.36 ±
1.45 and 0.94 ± 0.56 days respectively (Table 4). In other
words, PZH significantly lengthened the time of survival
after stroke. Our results suggest that PZH treatment
before the onset of stroke significantly lengthens the survi-
val of the animals after stroke.
Immunostaining of caspase-3
Cleaved caspase-3 (the activated form) expression by
immunostaining was significantly lower in hippocampus
in the ischemia with PZH treatment group (1A) com-
pared to the ischemia control group (2A) (3.06 ± 1.97;
14.1 ± 2.93 cells/mm
2; P < 0.001) and in cerebellum
(7.97 ± 1.38; 10.7 ± 1.44; P < 0.001) (Figure 3), suggest-
ing that PZH may significantly prevent apoptosis in
these two brain areas as caused by the chronic ischemia.
Representative photos of cleaved caspase-3 positive
staining in hippocampus and cerebellum are shown in
Figure 4.
Proteomic analysis
There were nine and 13 differentially expressed proteins
identified for hippocampus and cerebellum respectively
(Tables 5 and 6) between the ischemia with PZH treat-
ment group (1B) and the ischemia control group (2B).
Cytochrome b-c1 complex subunit 2 (QCR2) was down-
regulated in both the hippocampus and cerebellum.
Both DAVID and GOTM analyses revealed that the
most significant association for the hippocampus and
cerebellum was with mitochondrial membrane (Table
7). Full clustering results from DAVID and GOTM for
the hippocampus (Additional file 1) and cerebellum
(Additional file 2) and the directed acyclic graphs
(DAG) of the clustering results from GOTM for hippo-
campus (Additional file 3) and cerebellum (Additional
file 4) are provided as additional files. Representative gel
images showed that there were no other apparent inhi-
b i t i o n so ro v e re x p r e s s i o n so fp r o t e i n si nv a r i o u ss a m -
ples from the two groups except those mentioned above
(Figure 5).
Discussion
Using biochemical, histological and proteomic methods,
we found that PZH significantly decreased cell death in
hippocampus and cerebellum caused by chronic ische-
mia and hypertensive stroke by possibly preventing
brain cells from apoptosis and mitochondria reactive
oxygen species (ROS) damage.
We used the ELISA method to detect histone-asso-
ciated DNA fragments or nucleosomes to study cell
death in the hippocampus and the cerebellum two
weeks after ischemia in SHR (i.e. ischemia co-existed
with hypertension) and in WKY (i.e. ischemia without
Figure 2 Cell death assay results in SHRsp. Cell death in
hippocampus and cerebellum samples from SHR-sp. Group 5A was
fed with daily PZH until the stroke occurred, while Group 5B was
given saline. Hippocampus and cerebellum tissues were sampled
when the rats died after stroke. SHRsp treated with PZH (Group 5A)
before stroke showed significantly less (*P < 0.05) cell death as
compared to those rats without PZH treatment (Group 5B) in both
hippocampus and cerebellum.
Table 3 Neurological scores at the onset of stroke
Number of SHRsp
Score





PZH treated (5A)* 1 7 2 4 8 (57%) 6 (43%) 14
Control (5B) 0 6 5 6 6 (35%) 11 (65%) 17
#score when stroke occurred.
*Chi-square = 2.5 (P = 0.476) as compared with controls using individual
scores of 1, 2, 3 and 4.
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PZH treatment groups, the cell deaths were restored to
similar levels in the hippocampus as the sham operation
groups, whereas the ischemia groups showed significant
increases in cell death (Figure 1A). On the other hand,
there was no significant difference in the cerebellum
between groups (Figure 1B), suggesting that PZH could
significantly reduce brain cell death in affected area (e.g.
the hippocampus) caused by cerebral ischemia. The pro-
tective effects of PZH on ischemia in hippocampus were
effective with and without the presence of hypertension.
The bilateral CCA were occluded and ischemia would
be more severe at regions such as the hippocampus of
mid-brain area, while the blood supply to the posterior
part of the brain such as cerebellum would be less
affected because the vertebral arteries were intact hence
the ischemia would be less severe. Therefore, PZH did
not show any effect in cerebellum where the less severe
ischemia might not have caused significant cell death
(Figure 1B). Our choice of hippocampus and cerebellum
as the brain regions for study correctly identified two
regions with differential damage from the ischemia
caused by CCA occlusion.
SHRsp rats with PZH preventive treatment showed sig-
nificantly decreases in cell deaths as compared to the con-
trol group in both hippocampus and cerebellum (Figure
2). Though the stroke in SHRsp is a characteristic clinical
feature, the sites of cerebral lesions are somewhat different
from those in cerebrovascular diseases; however, the cere-
brovascular changes are consistent with those in malignant
hypertension [17]. The decreases in cell deaths by PZH at
hippocampus and cerebellum caused may be beneficial;
however, we also noted that the increases of cell deaths
caused by ischemia are only two folds although statistically
significant (Figure 1), suggesting that ligation of CCA as a
partial and chronic ischemia method may not cause mas-
sive cell apoptosis. In addition, we sacrificed the rats two
weeks after ligation to examine its chronic effect; any
apoptosis caused by the acute effect might have recovered.
Nevertheless, two folds of statistically significant increases
demonstrated that PZH preventive treatment worked
against these increases in apoptosis.
Table 4 (B) Score, time of onset of stroke, and time of death of the PTH treated (5A) and control (5B) SHRsp
Group Value Score Stroke (day) Death (day) Death since stroke (day)
PZH treated (5A) Mean 2.64 52.71 55.07 2.36
SD 1.01 7.58 8.27 1.45
Control (5B) Mean 3.00 54.12 55.06 0.94
SD 0.87 10.33 9.94 0.56
p value** 0.2973 0.6757 0.9970 0.000837
**comparing between PZH treated and control groups.
Figure 3 Immunostaining results of SHR. Cleaved caspase-3 expressions in hippocampus and cerebellum of Groups 1A and 2A PZH treatment
significantly decreased apoptosis by lowering of the active cleaved caspase-3 numbers in both cerebellum and hippocampus (*P < 0.001).
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Page 8 of 14Figure 4 Microscopic images of immunostaining. Representative microscopic photos of cleaved caspase-3 positive staining cells in
hippocampus (a, b) and cerebellum (c, d, e). Caspase-3 immunostaining of hippocampus samples from (a) ischemia control group 2A and (b)
ischemia with PZH treatment group 1A. (a) Caspase-3 positive cells (arrows) were seen at the molecular (M), pyramidal (Py) and polymorphic (P)
layers of hippocampus from a rat of ischemia control group, ×200. (b) Few caspase-3 positive cells (arrow) were found mainly in the pyramidal
layer of hippocampus from a rat of ischemia with PZH treatment group, ×200. Caspase-3 immunostaining of cerebellum samples from (c, d)
ischemia control group 2A and ischemia with (e) PZH treatment group 1A. (c) Caspase-3 positive cells were seen at the Purkinje layer (arrows) of
cerebellum from a rat of ischemia control group, ×200. (d) A larger magnification of (c) to show the caspase-3 positive cells (arrows), ×400. (e)
Only isolated caspase-3 positive cells (arrow) were found along the Purkinje layer of cerebellum from a rat of ischemia with PZH treatment
group, ×200.
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Page 9 of 14Furthermore, our results of immunostaining were con-
sistent with the cell death assay. Caspase-3 positive cell
counts were significantly reduced in the SHR ischemia
with PZH treatment as compared to the SHR ischemia
control group for both hippocampus and cerebellum
(Figure 3). Consistent with cell death assay results; the
caspase-3 positive cell numbers were not large, indicat-
ing the milder effects of chronic ischemia of ligation of
CCA. PZH preventive effects on apoptosis were also sta-
tistically significant, suggesting that apoptosis was pre-
vented by PZH in ischemia in both brain regions of
SHR.
As to the possible mechanisms of PZH protective
effects on ischemia and stroke, proteomic results indi-
cated that the cytochrome b-c1 complex subunit 2
(QCR2) was down-regulated in the ischemia with PZH
treatment group in both the hippocampus and cerebel-
lum as compared to the ischemia control group (Tables
5 and 6). QCR2 is one of the 11 protein constituents of
the ubiquinol:cytochrome c oxidoreductase (bc1 com-
plex) [43-45]. The bc1 complex as a core of the electro-
nic transfer chains is a component of the eukaryotic
respiratory chain in mitochondria catalyzing electron
transfer from ubiquinol to cytochrome c, which is
coupled to the translocation of protons across the mito-
chondrial inner membrane from the matrix space [43].
Thus, bc1 complex contributes to the electrochemical
proton gradient that drives adenosine triphosphate
synthesis. A Q-cycle mechanism accounts for the activ-
ity of the bc1 complex [45]. In the Q-cycle, the semiqui-
none, an intermediate produced at the Q0 site, has a
high reactivity with oxygen leading to the production of
reactive oxygen species (ROS) which cause damage to
the mitochondrial structure and its DNA [45,46]. It has
been suggested that this production of ROS may be the
major source of damage under some physiological and
pathological conditions [46,47]. While QCR2 is not the
protein constituent at the Q0 site, as a core protein of
the complex, the significant down-regulation of QCR2
by PZH may slow down the production of ROS. Our
results suggested that PZH minimized the adverse
effects of ROS production and oxidative damage which
was critical in chronic ischemia and hypertensive stroke
despite the fact that ROS production and damage is
Table 5 Lists of differentially expressed proteins identified by 2D-gel electrophoresis and mass spectrometric analysis











Q99MZ8 NP_116002 LASP1 -2.80 251 LIM and SH3 domain protein 1
P20788 NP_001008888 UCRI -2.67 448 Cytochrome b-c1 complex subunit Rieske, mitochondrial precursor
P09117 NP_036629 ALDOC -2.53 197 Fructose-bisphosphate aldolase C; Brain-type aldolase
P54311 NP_112249 GBB1 -2.53 170 Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1
P32551 NP_001006971 QCR2 -2.40 165 Cytochrome b-c1 complex subunit 2, mitochondrial precursor
P62260 NP_113791 1433E -2.40 296 14-3-3 protein epsilon; Mitochondrial import stimulation factor L subunit
Q5XIH3 NP_001006973 NDUV1 -2.00 236 NADH dehydrogenase [ubiquinone] flavoprotein 1, mitochondrial precursor
P63039 NP_071565 CH60 +2.63 595 60 kDa heat shock protein, mitochondrial precursor
P08461 NP_112287 ODP2 +3.20 178 Dihydrolipoyllysine-residue acetyltransferase component of pyruvate dehydrogenase
complex, mitochondrial precursor
*- denotes down-regulated and + denotes up-regulated comparing the ischemia with PZH group (1B) to the ischemia control group (2B).
Table 6 Lists of differentially expressed proteins identified by 2D-gel electrophoresis and mass spectrometric analysis
with a matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF)/TOF tandem mass spectrometer of
cerebellum samples
Swiss-Prot Ac Refseq Protein Protein ID Fold* Protein score Protein Name
P15999 NP_075581 ATPA -5.60 460 ATP synthase subunit alpha, mitochondrial precursor
P32551 NP_001006971 QCR2 -5.07 99 Cytochrome b-c1 complex subunit 2, mitochondrial precursor
P00507 NP_037309 AATM -4.17 446 Aspartate aminotransferase, mitochondrial precursor
P01026 NP_058690 CO3 -2.80 146 Complement C3 precursor
Q9JHU0 NP_075412 DPYL5 -2.93 412 Dihydropyrimidinase-related protein 5
O08651 NP_113808 SERA -2.67 67 D-3-phosphoglycerate dehydrogenase
P67779 NP_114039 PHB -2.13 561 Prohibitin
P10860 NP_036702 DHE3 -2.03 443 Glutamate dehydrogenase 1, mitochondrial precursor
Q63270 NP_059017 ACOC +2.00 154 Cytoplasmic aconitate hydratase
*- denotes down-regulated and + denotes up-regulated comparing the ischemia with PZH group (1A) to the ischemia control group (2A).
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Page 10 of 14usually an early event of ischemia insult [46,47]. On the
other hand, QCR2 decreased more in cerebellum than
in hippocampus (Tables 5 and 6) while cerebellum
showed insignificant cell deaths induced by ischemia
comparing to hippocampus showed significant cell
death (Figure 1). To confirm our findings, future studies
on PZH should examine the oxidative status or ROS
generation in particular to the role of QCR2.
In the hippocampus, another protein constituent of
bc1 complex, namely cytochrome bc1 complex subunit
Rieske (UCRI), was also significantly down-regulated in
the PZH group as compared to the control group
(Tables 5 and 6). QCR2 and UCRI were placed by
D A V I Da n dG O T Mw i t hr e s p e c tt ot h e i rf u n c t i o n a l
annotations together in the most significant groups
(Tables 5 and 6) with other several proteins associated
with mitochondrial membrane. Indeed, six out of the
nine proteins differentially expressed in hippocampus
and five out of the 13 proteins for cerebellum of the
PZH and control groups were associated with
Table 7 The most significant cell component group of functional annotation by DAVID and GOTM of the differentially
expressed proteins of the hippocampus and cerebellum by 2D gel electrophoresis and mass spectrometric analysis
with a matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF)/TOF tandem mass spectrometer
Method Brain region Term P value Benjamini* Proteins




0.0000317 0.02553 NP_075581, NP_001006971, NP_036702, NP_114039, NP_037309.
GOTM Hippocampus Mitochondrial
membrane part
0.000000279 Nil NP_001006973, NP_071565*, NP_001008888, NP_001006971.
Cerebellum Mitochondrial inner
membrane
0.0016 Nil NP_036702, NP_075581, NP_001006971, NP_037309.
*
P value by Benjamini correction in DAVID analysis. Other multiple testing correction techniques, Bonferroni and FDR, as provided by DAVID gave the samep
values
Figure 5 Representative images of 2D electrophoresis gels. Representative 2D electrophoresis gel photos of brain tissue samples from (A)
SHR of ischemia with PZH preventive treatment and (B) SHR of ischemia control. The red circle indicates cytochrome b-c1 complex subunit 2,
mitochondrial precursor (QCR2), the protein that down-regulated in both hippocampus and cerebellum in PZH treatment group as compared to
controls. There was also no overall inhibition or over expression of proteins in the PZH treatment sample compared with the control sample.
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Page 11 of 14mitochondria as identified by DAVID (Table 7). For
example, the aconitase was up-regulated and prevented
oxidative stress [48] and apoptosis [49]. These up- or
down-regulated proteins may also play roles in the PZH
preventive effects on chronic ischemia and hypertensive
stroke. Our results suggested that the target organelle
for PZH preventive effects was likely to be the mito-
chondria and that the target molecule(s) could be the
bc1 complex or its subunits at least for the hippocampus
and cerebellum, which may also be true for the rest of
the brain.
One potential limitation of our functional annotation
analyses by DAVID and GOTM is the protein lists
which are too short from the recommended 100 genes/
proteins for avoiding spurious results [40]. We could
have increased the protein lists by lowering the factor
for creating the differentially expressed protein results
from the proteomic experiment; however, considering
the variation in 2D proteomic experiment, we think the
factor of two was appropriate [39]. Furthermore, to
avoid over inference and hence false interpretation, we
used only the most significant terms from hippocampus
and cerebellum samples by DAVID and GOTM which
showed that consistently the mitochondrial membrane
was involved and both, QCR2 and UCR1 were among
the protein lists. In addition, as mentioned above, six
out of the nine proteins for hippocampus and five out
of the 13 proteins for cerebellum were functionally
annotated with mitochondria by DAVID (Table 7) and
similarly by Protein Information Resource (PIR) (Addi-
tional file 5). There was a significant association of the
PZH preventive treatment and the functions of mito-
chondria in particular with the bc1complex in the aspect
of ROS production.
There are the following points worth noting. Firstly,
PZH treatment may have independent effects from
ischemia on protein expressions and thus the lists of dif-
ferentially expressed proteins were unrelated with ische-
mia; however, the composition of PZH [9,24,25]
suggests that PZH should have effects on ischemia.
Especially the proteins are involved in pathways and
organelles for defense against stress, insult or damage.
Secondly, the nature of ligation of CCA and cell death
and caspase-3 results (Figures 1, 2, 3) suggests that cere-
bellum would be less affected than hippocampus and
w o u l de x p e c tas h o r t e rd i f f e rentially expressed protein
list for cerebellum. Our results showed cerebellum had
a longer list (Tables 5 and 6). It is difficult to correlate
proteomic results with cell death and capase-3 results
and in view of the variable 2D electrophoretic results, a
shorter protein list for hippocampus than cerebellum
may not be interpreted as hippocampus was less
affected. This could be due to (1) both protein lists are
short and (2) proteomic analysis examines individual
protein expressions while cell death and caspase-3
reflect the functions of many proteins together. There-
fore, discrepancies between them should not be seen as
contradictory or inconclusive.
Mitochondria play a pivotal role in apoptotic pathways
[50]. Cytochrome c release triggered by Bax from the
mitochondrial membrane initiates apoptosis. Down-
stream effectors such as caspase-3 are activated leading
to apoptosis [51]. The proteomic results did not provide
direct evidence as to whether proteins along the apopto-
tic pathways were up- or down- regulated. However, as
the differentially expressed proteins were significantly
associated with the mitochondria and their membrane
parts, the apoptosis pathway may still be affected.
Indeed, our other results showed that cleaved caspase-3
was significantly decreased by PZH preventive treatment
in ischemia (Figure 3). Taken together, PZH may affect
the electron transfer chain at mitochondria preventing
ROS and oxidative damage and maybe the apoptotic
pathways, leading to the prevention of cell death due to
apoptosis or necrosis as caused by chronic ischemia or
hypertensive stroke at hippocampus and cerebellum.
Lastly, while PZH did not prevent the progress of
stroke and the subsequent fatality, it significantly
delayed the death after stroke had occurred (Tables 3
and 4). This is important in two ways: firstly, we pro-
vided no clinical treatment to the rats after stroke had
occurred, but this certainly would not be the case for
human patients who have suffered a stroke [52]. There-
fore, the slightly lesser severity of stroke and significant
delay in death would afford a better outcome for
human patients. Secondly, stroke in SHRsp rats is
imminent, whereas in humans stroke is not a definite
outcome, even in hypertensive patients. We may specu-
late and anticipate that the preventive effects of PZH on
human cases of stroke may be very significantly
beneficial.
Conclusion
PZH showed significant preventive effects on limiting
t h ed a m a g eo ri n j u r yc a u s e db yi s c h e m i aa n ds t r o k e
with and without hypertension in rats. The mechanism
of these effects was possibly related to prevention of cell
death from apoptosis or ROS and oxidative damage of
mitochondria. Further studies to elucidate this mechan-
ism are warranted.
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